araag2/HINT huggingface dataset:
Clinical trial NCT00505037 (phase 2, status: completed)
Conditions: hyperphosphatemia, chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: asp1585, placebo, sevelamer hydrochloride
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Stable CKD patients who are currently on hemodialysis three times a week for at least
             12 weeks prior to the acquisition of informed consent

          -  Patients on stable dose(s) of phosphate binder(s) for at least 28 days prior to the
             acquisition of informed consent.

          -  Patients on stable dose(s) of Vitamin D or calcitonin agent for at least 28 days prior
             to the acquisition of informed consent, in case patients are treated by those agents

        Exclusion Criteria:

          -  History of major gastrointestinal surgery, or swallowing disorders, bowel obstruction,
             hemorrhagic gastrointestinal lesion

          -  Continuous severe constipation/diarrhea.

          -  History of parathyroid intervention [parathyroidectomy（PTx），percutaneous ethanol
             injection therapy（PEIT）etc.] within 1 year of the acquisition of informed consent

          -  Diet restriction such as fasting and/or excessive dieting

          -  Uncontrolled hypertension
Clinical trial NCT01350362 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: tideglusib, tideglusib, tideglusib, placebo
SMILES: O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1, O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1, O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          1. Men and women (of non-childbearing potential) with a diagnosis of probable Alzheimer's
             disease.

          2. Age of 50 to 85 years.

          3. MMSE score 14 to 26.

          4. Well-tolerated treatment with one of the approved Acetylcholinesterase-Inhibitors
             and/or Memantine in a stable dose

        Main Exclusion Criteria:

          1. Significant psychiatric on medical disease.

          2. Any chronic liver disease as indicated by out of range values of ALAT, ASAT or direct
             bilirubin, clinically relevant hepatic steatosis or other clinical manifestations of
             liver disease

          3. Chronic daily drug intake of excluded concomitant medications.

          4. Enrollment in another investigational drug study within 3 months before the baseline
             visit.
Clinical trial NCT00491127 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: gemcitabine, cisplatin, dexamethasone
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  The patients must have a histological diagnosis of aggressive non-Hodgkin's lymphoma
             including the following sub-categories of the WHO classification:

               -  Diffuse large B-cell lymphoma and its variants (immunoblastic, Burkitt-like,
                  sclerosis of mediastinum, large B-cell MALT, rich in T-cells and anaplastic
                  B-cell lymphoma)

               -  Peripheral T-cell lymphoma

               -  Anaplastic lymphoma of large T-cells /null cells

          -  Patients are eligible if they have documented evidence of progression after prior
             first-line chemotherapy containing anthracyclines associated or not with Rituximab.
             Patients with refractory disease to first line of treatment are also eligible.

          -  ECOG PS (performance status) less than or equal to 2

          -  Presence of bidimensionally measurable disease in accordance with WHO criteria.

        Exclusion Criteria:

          -  Involvement of the CNS.

          -  Any medical condition which contraindicates the degree of hydration required for the
             safe use of cisplatin.

          -  Intermediate degree lymphoma derived from the malignant transformation of a previous
             low-grade lymphoma.

          -  Active infection (in the opinion of the investigator).
Clinical trial NCT00732810 (phase 2, status: completed)
Conditions: breast neoplasms, carcinoma, non-small-cell lung
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, D02.20, D02.21, D02.22
Drugs: sch 727965, capecitabine, erlotinib
SMILES: CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Age >=18 years, either sex, any race.

          -  Histologically or cytologically confirmed breast cancer or NSCLC; and radiographic or
             clinically advanced disease.

          -  BREAST CANCER:

               -  participant must have previously received both a taxane and an anthracycline
                  (unless anthracycline therapy is contraindicated) in the adjuvant and/or
                  metastatic setting,

               -  participant with HER2-positive disease must have progressed after trastuzumab and
                  concomitant or subsequent lapatinib,

               -  participant must have received at least one, but no more than two prior regimens
                  for recurrent or metastatic disease (endocrine and biologic therapies do not
                  count as chemotherapeutic regimens).

          -  NSCLC: at least one, but no more than two prior chemotherapeutic regimens for advanced
             disease.

          -  Measurable disease by the RECIST.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  Adequate hematologic, renal, and hepatic organ function and laboratory parameters.

          -  Ability to swallow tablets.

        Exclusion Criteria:

          -  Known brain metastases. For NSCLC only, a participant with central nervous system
             metastasis is eligible provided the participant has received definitive local therapy
             (ie, radiation therapy or surgery), has stopped receiving treatment with
             corticosteroids, and is without symptoms for at least 4 weeks before randomization.

          -  History of previous radiation therapy to >25% of total bone marrow.

          -  Known HIV infection.

          -  Known active hepatitis B or hepatitis C.

          -  Previous treatment with SCH 727965 or other cyclin-dependent-kinase inhibitors.

          -  BREAST CANCER:

               -  known dihydropyrimidine dehydrogenase deficiency,

               -  previous treatment with capecitabine.

          -  NSCLC: previous treatment with erlotinib.
Clinical trial NCT00280735 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, docetaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed non-small cell lung cancer

               -  Stage I-IIIA disease

          -  Must have undergone a complete resection

          -  Must begin adjuvant chemotherapy within 8 weeks of surgical resection

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

          -  Platelet count ≥ 100,000/mm^3

          -  Serum creatinine normal OR creatinine clearance ≥ 40 mL/min

          -  Bilirubin normal

          -  Alkaline phosphatase (AP), Aspartate aminotransferase (AST), and Alanine transaminase
             (ALT) must meet 1 of the following criteria:

               -  AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)

               -  AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN

               -  AP ≤ 5 times ULN AND AST and ALT normal

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 3 months
             after study therapy

        Exclusion criteria:

          -  Patients with a history of severe hypersensitivity to docetaxel or polysorbate 80 are
             excluded.

          -  Women who are currently or planning to breast feed.

          -  Those with peripheral neuropathy ≥ grade 2

        PRIOR CONCURRENT THERAPY:

          -  2-8 weeks since prior surgery and recovered
Clinical trial NCT00003729 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cytarabine, fludarabine phosphate, idarubicin
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Cytologically diagnosed relapsed or refractory acute lymphocytic
        leukemia previously treated with front line therapy FAB L1 or L2 Bone marrow relapse either
        isolated or associated with CNS or testicular relapse Bone marrow blast cells greater than
        10% No isolated CNS relapse

        PATIENT CHARACTERISTICS: Age: Under 18 Performance status: WHO 0-2 Play-performance scale
        at least 60% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin
        less than 2.5 times normal Renal: Creatinine less than 2.5 times normal Cardiovascular: No
        symptoms of cardiac failure No decline of ejection fraction by more than 20% of the lower
        limit of normal Shortening fraction at least 25% Other: No psychological, familial,
        sociological or geographical condition that would hamper compliance No uncontrolled
        infection

        PRIOR CONCURRENT THERAPY: At least 6 months since prior autologous bone marrow
        transplantation No prior allogeneic bone marrow transplantation No concurrent treatment
        with other experimental drug
Clinical trial NCT01607294 (phase 2, status: completed)
Conditions: hyperlipidemia, type 2 diabetes
ICD codes: E78.2, E78.49, E78.5, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: etc-1002, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes meeting all of the following:

          -  Minimum 6 month history of diabetes prior to screening visit;

          -  Fasting C-peptide ≥ 0.8 ng/mL at screening visit;

          -  HbA1C at screening visit 7-10%;

          -  Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose
             regulating drugs and supplements.

          -  BMI at screening visit from 25-35 kg/m2;

          -  LDL-C at screening ≥ 100 mg/dL
Clinical trial NCT01443403 (phase 2, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: placebo, naldemedine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects aged 18 years or older at time of informed consent with non-malignant chronic
             pain experiencing opioid-induced constipation

          -  Subjects with < 3 spontaneous bowel movements a week and experiencing bowel symptoms

          -  Subjects receiving chronic opioid therapy due to non-malignant pain for ≥ 3 months

        Exclusion Criteria:

          -  Evidence of clinically significant gastrointestinal disease

          -  History of chronic constipation prior to starting analgesic medication or any
             potential non-opioid cause of bowel dysfunction that may be a major contributor to the
             constipation

          -  Severe constipation that has not been appropriately managed such that the subject is
             at immediate risk of developing serious complications of constipation
Clinical trial NCT00630825 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus >3 months by history prior to entering the trial, based on
             disease diagnostic criteria from the American Diabetes Association (ADA 2007).

          -  Men or women 18 years of age or older. Women must have a negative pregnancy test and
             be willing to use birth control during study duration and one month post.

          -  Have glycosylated hemoglobin (HbA1c) of >7.0% to ≤10.5% as determined by central
             laboratory at screening.

          -  Have a body mass index (BMI) between 27 and 40 kilograms/meter squared (kg/m^2),
             inclusive.

          -  Have been on the same doses for 3 months of any approved combination of 2 oral
             antihyperglycemic medications in any combination of the following: sulfonylureas (e.g.
             Chlorpropamide or Diabinese, Glimepiride or Amaryl, Tolbutamide or Orinase, Tolazamide
             or Tolinase, Glipizide or Glucotrol, Glyburide also known as Micronase, Diabeta, or
             Glynase), biguanides (e.g. Glucophage or metformin), thiazolidinediones (e.g.
             Rosiglitazone or Avandia, or Pioglitazone or Actos), or dipeptidyl peptidase 4
             (DPP-IV) inhibitors (e.g. Sitagliptin or Januvia). A combination pill of any 2 of
             these drugs is allowed (1 only), (e.g. Metformin and Glipizide or Metaglip), (e.g.
             Metformin and Glyburide or Glucovance), (e.g. Pioglitazone and Glimepiride or
             Duetact), or (e.g. Sitagliptin and Metformin or Janumet).

        Exclusion Criteria:

          -  Have known Type 1 Diabetes Mellitus

          -  Have taken glucagon-like peptide-1 (GLP-1) or any GLP-1 analog drug (Byetta)

          -  Have a history of unstable angina, heart attack (myocardial infarction), heart
             arrhythmia (ventricular), congestive heart failure, or other coronary intervention
             (percutaneous transluminal coronary angioplasty [PTCA], open heart surgery, or
             coronary artery bypass graft [CABG]), a transient ischemic attack (TIA) or stroke
             (cerebrovascular accident) in the last 6 months prior to screening.

          -  Have acute or chronic hepatitis or elevated liver function tests (alanine
             transaminase), a history of chronic or recurrent pancreatitis. Have renal disease or a
             serum creatinine (blood test) >2 milligrams per deciliter (mg/dL). If taking
             biguanides (e.g. metformin or Glucophage), or DPP-IV inhibitors (e.g. Sitagliptin or
             Januvia or Janumet), creatinine must be ≤1.5 mg/dL.

          -  Currently taking prescription or over the counter medications to prevent weight loss.
Clinical trial NCT00631202 (phase 2, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Molecular diagnosis of FA based on a homozygous GAA expansion within the FRDA with a
             triplet repeat sequence in the pathological range.

          -  Age >18, <50 years

        Exclusion Criteria:

          -  Failure to meet one of the inclusion criteria

          -  Patients in treatment with Idebenone

          -  Wheelchair bound patients

          -  Significant renal, hepatic or haematological disease

          -  Positive history for arterial or venous thrombosis

          -  Acute diseases that might interfere with the study

          -  Positive history for arterial hypertension

          -  Present or programmed pregnancy

          -  Known hypersensitivity to study drug

          -  Other unacceptable concomitant medications (in particular agents thought to have a
             neuroprotective potential as tocopherol, amantadine, memantine, free radical
             scavengers).
Clinical trial NCT00565331 (phase 2/phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: rituximab, placebo
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Renal transplant recipients

          -  Signed, dated, and witnessed IRB approved informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Living donor, who is HLA identical.

          -  Hemolytic uremic syndrome as original kidney disease.

          -  Focal segmental glomerulosclerosis that had recurred in a previous graft.

          -  More than two previously failed grafts and/or PRA > 85%.

          -  Previous treatment with anti-CD20 antibodies.

          -  Diabetes mellitus that is currently not treated with insulin.

          -  Total white blood cell count <3,000/mm3 or platelet count <75,000/mm3.

          -  Active infection with hepatitis B, hepatitis C, or HIV.

          -  History of tuberculosis
Clinical trial NCT00384774 (phase 2, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: lasmiditan, placebo
SMILES: CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1
             and 1.2.1 (2004)

          -  History of migraine of at least 1 year

          -  Migraine onset before the age of 50 years

          -  History of 1 - 8 migraine attacks per month

          -  Male or female subjects aged 18 to 65 years

          -  Female patients of child-bearing potential must be using a highly effective form of
             contraception (eg combined oral contraceptive, IUD, abstinence, vasectomized partner)

          -  Able and willing to return to the clinic for treatment within 4 hours of the onset of
             a migraine headache

          -  Able and willing to give written informed consent

        Exclusion Criteria:

          -  History of life threatening or intolerable adverse reaction to any triptan

          -  Use of prescription migraine prophylactic drugs

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential not using highly effective contraception

          -  History or evidence of coronary artery disease, ischemic or hemorrhagic stroke,
             epilepsy or any other condition placing the patient at increased risk of seizures

          -  History of hypertension (controlled or uncontrolled)

          -  Sitting BP >160mmHg systolic or >90mmHg diastolic on 2 repeated measurements at
             screening

          -  Current use of hemodynamically active cardiovascular drugs

          -  History within the previous 3 years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol

          -  Significant renal impairment

          -  Previous participation in this clinical trial

          -  Participation in any clinical trial of an experimental drug or device in the previous
             30 days

          -  Any medical condition or laboratory test which in the judgment of the investigator
             makes the patient unsuitable for the study

          -  Relatives of, or staff directly reporting to, the investigator

          -  Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to
             any excipient of COL-144
Clinical trial NCT01668680 (phase 2, status: terminated)
Conditions: colorectal cancer metastatic
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, celecoxib and methotrexate
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    no satisfactory acrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologic (or cytologic) proof of colorectal carcinoma (CRC).

          2. Age: between 18 and 80.

          3. Sex: both sexes.

          4. Previous treatment for metastatic disease is limited to FOLFIRI+ bevacizumab.

          5. Prior adjuvant chemotherapy, with a fluoropyrimidine and/or Oxaliplatin, is allowed.

          6. Prior radiotherapy, either as adjuvant treatment or palliation of metastatic sites is
             allowed, provided that there are other non-irradiated foci of disease for evaluation.

          7. Persistent remission, either complete, partial or minimal response (CR, PR or MR) or
             stable disease (SD), one year+/-one month from initiation of first line treatment for
             mCRC.

          8. Asymptomatic patients at break from chemotherapy.

          9. Intact organ function, including complete blood counts (CBC) showing normal values or
             any toxicity limited to grade 1 and blood chemistry (SMA) showing liver and renal
             functions < 1.5 upper normal limit (UNL).

         10. Capability to understand and to sign the informed consent.

        Exclusion Criteria:

          1. Concurrent any other cancer (except BCC or squamous cell carcinoma of skin).

          2. Inability to adhere to monthly visits to the oncology unit for evaluation.

          3. Presence of brain metastases.

          4. Any current or recent (within the last month) continuous treatment by steroids or by
             NSAIDs, or with therapeutic doses of anticoagulants for any reason.

          5. Previous radiotherapy to the only site of measurable disease.

          6. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated
             respiratory, cardiac including arrhythmias, hepatic or renal disease), and/or
             existence of active peptic ulcer (clinically and/or by gastroscopy).
Clinical trial NCT00655733 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: hmpl-004, placebo
SMILES: [H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have active confirmed Crohn's Disease (confirmed radiographically, endoscopic, or
             histologically), with a CDAI of 220-400 at baseline screen

        Exclusion Criteria:

          -  They have received anti-TNF-α antibody within 3 months of starting study medication,
             or cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil within 2 months of
             starting study medication